SCHEMBL3798463

SCHEMBL3798463

CCN1CCC(Oc2ccccc2Nc2ncnc3scc(C)c23)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.50
LMNA P02545 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
NOD2 Q9HC29 1/20 0.50
MKNK1 Q9BUB5 4/20 0.40
MKNK2 Q9HBH9 3/20 0.40
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CDK2 P24941 2/20 0.39
FLT3 P36888 2/20 0.39
CCNA1 P78396 2/20 0.39
IRAK4 Q9NWZ3 1/20 0.38
PIP4K2C Q8TBX8 1/20 0.38
MRGPRX1 Q96LB2 1/20 0.38
SRC P12931 3/20 0.38
DRD4 P21917 1/20 0.37
MAPT P10636 2/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3795405 0.85 MAPK1 (0.50) RAB9ALMNARXFP1MKNK1MKNK2
SCHEMBL3795373 0.84 EGFR (0.42) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL3803043 0.84 PIP4K2C (0.46) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL3797074 0.84 LMNA (0.42) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL3799478 0.83 LMNA (0.45) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL4594180 0.83 LMNA (0.41) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL4593797 0.83 RAB9A (0.43) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL3803590 0.83 LMNA (0.45) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL3799186 0.82 PIK3CD (0.41) RAB9ALMNARXFP1NOD2MKNK1
SCHEMBL3797069 0.82 PIP4K2C (0.42) RAB9ALMNARXFP1NOD2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US claimed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO claimed
WO-2007059905-A2 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-05-31 WO claimed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP disclosed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO disclosed
WO-2007059905-A2 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-05-31 WO disclosed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, PDXK RAB9A 2822/4885LMNA 4401/4885RXFP1 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.